FDA GRAS-approved lantibiotic (34 amino acids) produced by Lactococcus lactis with a dual antimicrobial mechanism — binds lipid II to block cell wall synthesis AND forms 2 nm transmembrane pores for rapid bacterial killing at MIC 0.5-4 μg/mL against gram-positive pathogens including MRSA and Listeria monocytogenes — the only antimicrobial peptide with over 50 years of documented safe human consumption
Written by — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Topical: Applied onto the skin as a cream, gel, or lotion — it works mainly where you put it.
Bioavailability Local — acts mainly at the skin; little reaches the bloodstream.
10-50 mcg/mL applied to the affected area
Frequency
Once or twice daily
Duration
Research protocol-dependent (typically 1-4 weeks)
Topical antimicrobial concentration range used in wound-care and infection-control research . Investigational; not an approved human therapeutic route.
Timing
Best time to take
Take Nisin at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
Nisin can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
Nisin should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
You've tolerated the current dose for the recommended period without significant side effects
Therapeutic goals haven't been met at the current dose level
Your healthcare provider recommends dose escalation based on your response
Lab work or clinical assessments support a higher dose
Decrease if
Side effects are bothersome or impacting daily life despite management strategies
You experience any signs of an adverse reaction
Lab results indicate the need for dose reduction
Your healthcare provider recommends a lower dose based on your response
Signs of right dose
Therapeutic goals being met with minimal side effects
Stable and consistent response to treatment
Lab values or clinical markers trending in the right direction
Good tolerance with manageable or absent side effects
Administration
How do I use Nisin?
Reconstitution
What you need
Nisin in its prescribed form
Clean, dry storage container
Measuring device if applicable (oral syringe, measuring cup)
Calendar or reminder app for dosing schedule
Injection
Route
Nisin is administered Oral (food-grade preservative, GRAS)—no injection required
Best sites
location_onNot applicable—this is not an injectable formulation
Storage
Before reconstitution
Store Nisin in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Nisin should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
warningSigns of degradation — discard the vial
Solution appears cloudy, discolored, or contains visible particles (should be clear)
Product has been exposed to temperatures outside the recommended storage range
Product has been frozen (unless specifically designed for freeze-thaw stability)
Expiration date has passed or reconstituted solution has exceeded its use-by date
Unusual odor, color change, or visible contamination
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Oral (food-grade preservative, GRAS)—rotate sites if applicable
Maintain a consistent schedule for optimal results with Nisin. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is Nisin safe?
Side effects
Commonly reported: No significant effects at dietary levels, Mild GI discomfort at research doses, Local irritation (topical use)
Less common: Milk protein allergic reaction, Gram-negative overgrowth
warningSerious side effects
No documented serious adverse effects
emergencyStop and seek help if
Severe or worsening side effects that don't improve with dose adjustment or supportive care
Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
Your healthcare provider recommends discontinuation based on your clinical response
Development of any new medical condition that may be contraindicated with Nisin
Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
Abnormal lab results or clinical markers that suggest adverse effects
Nisin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
warningFlagged pairings
Alkaline formulations (pH >7) — nisin activity and stability decrease significantly above neutral pH, with degradation accelerating at alkaline conditions — Use with caution—discuss with your healthcare provider.
Proteolytic enzymes (trypsin, chymotrypsin at high concentrations) — while lanthionine bridges provide some resistance, extensive proteolysis can reduce activity — Use with caution—discuss with your healthcare provider.
High-fat food matrices without emulsification — nisin may partition into fat phase, reducing aqueous concentration and antimicrobial activity — Use with caution—discuss with your healthcare provider.
Not an FDA-approved drug. Nisin preparation is affirmed as GRAS (21 CFR 184.1538, 1988) only as a food antimicrobial, for example to inhibit Clostridium botulinum in pasteurized cheese spreads; therapeutic uses are investigational.
12016
New Insights into Nisin's Antibacterial Mechanism Revealed by Binding Studies with Synthetic Lipid II Analogues
't Hart P, Oppedijk SF, Breukink E, et al. · 2016PubMed
Nisin binds to bacterial lipid II through its pyrophosphate group, with the complete sugar unit required for tight binding and pore formation in bacterial membranes.
Synergistic anticancer activity of antimicrobial peptide nisin and doxorubicin against breast cancer cells via modulation of membrane permeability
Phetdee C, Naephrai S, Pradain M, Panporm Y, Ahmad U, Prangkio P · 2026PubMed
PLoS One 2026;21(6):e0352312 (PMID 42335141). Nisin was cytotoxic to MCF-7 and MDA-MB-231 breast cancer cells (IC50 5-8 µM) with lower toxicity to normal cells, permeabilized membranes preferentially via anionic lipids, and acted synergistically with doxorubicin to enhance apoptosis.
Combination therapy with nisin, urolithin B, and vincristine exhibits synergistic antiproliferative and pro-apoptotic effects against human lymphoma cells: evidence from proteomics
Al-Khazaleh AK, Alsherbiny MA, Chang D, et al. · 2025PubMed
Study (2014) elucidates the molecular mechanism of action and biological pathways by which nisin produces therapeutic effects.
Nisin-biogel against Staphylococcus aureus isolates from diabetic foot infections (topical antimicrobial concentrations)
Jesus C, Soares R, Cunha E, Grilo M, Tavares L, Oliveira M · 2021PubMed
In vitro study of nisin (as a nisin-biogel) against Staphylococcus aureus isolated from diabetic foot wound infections. The mean nisin MIC against these wound isolates was approximately 22.5 ug/mL, with sub-inhibitory concentrations (~2.8-11.25 ug/mL) tested for effects on virulence-gene expression. This supports the ~10-50 ug/mL range used in topical/wound antimicrobial formulation work; it is in-vitro/formulation research, not an approved human therapeutic dose.
Anticancer activity of cloned Nisin as an alternative therapy for MCF-7 breast cancer cell line
Said Taha S, Abdulrahman ZFA, Othman RT (2023) · 2023DOI
MTT assay reports nisin exhibits high and selective cytotoxicity against the MCF-7 breast cancer cell line with an IC50 value of 11.68 µg/ml (PMID 37807320). This is the source of the page's MCF-7 IC50 figure.
U.S. Food and Drug Administration (Electronic Code of Federal Regulations) · 1988ecfr.gov
Nisin preparation from Streptococcus lactis fermentation is affirmed as GRAS (53 FR 11250, 6 April 1988) for use as an antimicrobial to inhibit the outgrowth of Clostridium botulinum spores and toxin formation in pasteurized cheese spreads and process cheese spreads, at levels not exceeding good manufacturing practice. This is a food-ingredient status, not drug approval.